NASDAQ:PROF Profound Medical (PROF) Stock Price, News & Analysis $6.65 -0.43 (-6.07%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Profound Medical Stock (NASDAQ:PROF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Profound Medical alerts:Sign Up Key Stats Today's Range$6.57▼$7.0950-Day Range$6.37▼$8.3652-Week Range$3.76▼$8.95Volume69,979 shsAverage Volume155,336 shsMarket Capitalization$241.66 millionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingModerate Buy Company Overview Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches. The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia. The system features a closed-loop control mechanism that precisely adjusts ultrasound energy delivery based on continuous feedback from MR temperature mapping, enabling controlled ablation of prostate tissue while preserving surrounding structures. Founded in 2015, Profound Medical has secured regulatory approvals and clearances in multiple jurisdictions, including CE mark certification for the European market and FDA clearance in the United States. The company has established a network of clinical partners and distributors across North America and Europe, where its technology is being adopted in leading cancer centers and urology clinics. Profound Medical’s leadership comprises professionals with extensive experience in medical device development, clinical operations and regulatory affairs. The company continues to invest in research and development to expand its ultrasound platform for additional therapeutic indications and to support ongoing clinical studies aimed at improving patient outcomes.AI Generated. May Contain Errors. Read More Profound Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScorePROF MarketRank™: Profound Medical scored higher than 48% of companies evaluated by MarketBeat, and ranked 519th out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingProfound Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialProfound Medical has a consensus price target of $11.50, representing about 72.9% upside from its current price of $6.65.Amount of Analyst CoverageProfound Medical has only been the subject of 2 research reports in the past 90 days.Read more about Profound Medical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Profound Medical are expected to grow in the coming year, from ($0.81) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Profound Medical is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Profound Medical is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProfound Medical has a P/B Ratio of 4.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.04% of the float of Profound Medical has been sold short.Short Interest Ratio / Days to CoverProfound Medical has a short interest ratio ("days to cover") of 14.66, which indicates bearish sentiment.Change versus previous monthShort interest in Profound Medical has recently decreased by 2.56%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProfound Medical does not currently pay a dividend.Dividend GrowthProfound Medical does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.55 News SentimentProfound Medical has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Profound Medical this week, compared to 2 articles on an average week.Search Interest1 people have searched for PROF on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Profound Medical to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Profound Medical insiders have not sold or bought any company stock.Percentage Held by Insiders1.52% of the stock of Profound Medical is held by insiders.Percentage Held by Institutions47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Profound Medical's insider trading history. Receive PROF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PROF Stock News HeadlinesProfound’s Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days’August 17 at 8:51 AM | financialpost.comFProfound's Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days'August 17 at 8:30 AM | globenewswire.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.August 20 at 1:00 AM | Porter & Company (Ad)Profound Medical CFO Dewan Steps Down; Sobczyk Named Interim CFOAugust 15, 2026 | marketwatch.comProfound Medical names interim CFOAugust 14, 2026 | msn.comProfound Medical Announces Management ChangeAugust 14, 2026 | financialpost.comFProfound Medical Announces Management ChangeAugust 14, 2026 | markets.businessinsider.comProfound Medical Announces Management ChangeAugust 14, 2026 | globenewswire.comSee More Headlines PROF Stock Analysis - Frequently Asked Questions How have PROF shares performed this year? Profound Medical's stock was trading at $7.87 at the beginning of 2026. Since then, PROF shares have decreased by 15.5% and is now trading at $6.65. How were Profound Medical's earnings last quarter? Profound Medical (NASDAQ:PROF) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04. The business earned $2.48 million during the quarter, compared to the consensus estimate of $4.75 million. Profound Medical had a negative net margin of 171.57% and a negative trailing twelve-month return on equity of 63.03%. Read the conference call transcript. How do I buy shares of Profound Medical? Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Profound Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Profound Medical investors own include Alibaba Group (BABA), Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA) and Docusign (DOCU). Company Calendar Last Earnings8/06/2026Today8/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 PROF's financial health is in the Green zone, according to TradeSmith. PROF has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:PROF CIK1628808 Webwww.profoundmedical.com Phone(647) 476-1350Fax64-7847-3739Employees150Year Founded2008Price Target and Rating Average Price Target for Profound Medical$11.50 High Price Target$12.00 Low Price Target$11.00 Potential Upside/Downside+72.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.57 million Net Margins-171.57% Pretax Margin-170.37% Return on Equity-63.03% Return on Assets-51.24% Debt Debt-to-Equity RatioN/A Current Ratio6.46 Quick Ratio5.31 Sales & Book Value Annual Sales$16.10 million Price / Sales15.01 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book4.85Miscellaneous Outstanding Shares36,340,000Free Float35,789,000Market Cap$241.66 million OptionableOptionable Beta0.73 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:PROF) was last updated on 8/20/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredOne Ticker Tied to a Major White House Move You Should KnowLarry Benedict made 274 million dollars for his clients by spotting major market moves before they happened. ...Brownstone Research | SponsoredLook at this $5 stock’s addressA small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, ...Freedom Financial | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredAnthropic Just Became the First Trillion-Dollar Private CompanyAnthropic is now worth more than a trillion dollars, making it the first private company to reach that milesto...Weiss Ratings | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Profound Medical Please log in to your account or sign up in order to add this asset to your watchlist. Share Profound Medical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
